<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Parexel Biotech and Synairgen Collaborate on Phase III Trial for COVID-19 Treatment
Image Overlay - Parexel Biotech and Synairgen Collaborate on Phase III Trial for COVID-19 Treatment

Parexel Biotech and Synairgen Collaborate on Phase III Trial for COVID-19 Treatment

December 3, 2020

Parexel Biotech and Synairgen Collaborate on Phase III Trial for COVID-19 Treatment

Parexel Biotech has entered into a strategic collaboration with Synairgen. The two companies are working together on a phase III study of SNG001, an inhaled treatment for patients hospitalized with COVID-19. The trial aims to enroll 900 patients across 20 countries. Yourway has 21 strategically located depots around the world, to help advance all trials, at any scale, everywhere.

Back to Index
Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Longwood Healthcare Leaders

October 27-28, 2025
Mandarin Oriental Hotel, Boston

Precision in Pharma Supply Chain & Logistics Summit

November 17-18, 2025
Revere Hotel Boston Common

Media

Articles

Mitigating Risk in Drug Development: The Strategic Role of Phase I Research Units

Open chat
Come chat with us!
Hello! How can I help you?